# Arteris Chiplet Royalties Redefine Growth

> Arteris chiplet royalties could redefine growth story with 14% upside potential.
- Title: Arteris Chiplet Royalties Redefine Growth · Seekingalpha
- Summary: Arteris chiplet royalties could redefine growth story with 14% upside potential.
- Keywords: arteris, chiplet royalties, growth story, price target, q3 revenue, cycuity acquisition, ai licensing, cash flow, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4968214-arteris-chiplet-royalties-could-redefine-the-growth-story
- Published: 2026-11-14T18:54:36+00:00
- Read time: 1 min
- Topics: arteris, chiplet royalties, growth story, price target, q3 revenue, cycuity acquisition, ai licensing, cash flow, money, business
## Arteris Growth Outlook
Arteris remains a buy with a fy 2027 price target of $23, projecting 14% upside despite recent volatility and a 46% drawdown.
## Q3 Revenue Surge
Q3 revenue surged 48% year over year to $25.8m, driven by ai-related licensing and cycuity acquisition.
## Future Upside Drivers
Future upside hinges on accelerating acv plus royalties growth, particularly from chiplet designs expected to rise from 10% to 30-35% of all projects.
## Key takeaway

Arteris projects 14% upside to $23 price target by 2027 despite recent volatility and 46% drawdown.